Mode
Text Size
Log in / Sign up
Phase 3 Completed N=1,683 Prevention

Study of Safety and Efficacy of an Oral Contraceptive

Source: ClinicalTrials.gov NCT00391807 ↗
Enrolled (actual)
1,683
Serious AEs
0.9%
Results posted
Dec 2010
Primary outcomePrimary: Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population, — 2.554 Pregnancy Rate

Summary

This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.

Outcome Measures

OutcomeResultp-value
PRIMARY
Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population,
2.554 —
PRIMARY
Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18-45, MITT Population
2.167 —
SECONDARY
Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 2, MITT Population
3.21 —
SECONDARY
Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 6, MITT Population
2.00 —
SECONDARY
Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 13, MITT Population
1.81 —
SECONDARY
Percentage of Subjects With Withdrawal Bleeding (%), Cycle 2, MITT Population
34.8 —
SECONDARY
Percentage of Subjects With Withdrawal Bleeding (%), Cycle 6, MITT Population
25.0 —
SECONDARY
Percentage of Subjects With Withdrawal Bleeding (%), Cycle 13, MITT Population
22.4 —
SECONDARY
Median Duration of Withdrawal Bleeding, Cycle 2, MITT Population
3.93 —
SECONDARY
Median Duration of Withdrawal Bleeding, Cycle 6, MITT Population
3.99 —
SECONDARY
Median Duration of Withdrawal Bleeding, Cycle 12, MITT Population
3.85 —
SECONDARY
Total Number of Bleeding Days Per Cycle, Cycle 2, MITT Population
4.57 —
SECONDARY
Total Number of Bleeding Days Per Cycle, Cycle 6, MITT Population
3.00 —
SECONDARY
Total Number of Bleeding Days Per Cycle, Cycle 13, MITT Population
3.36 —
SECONDARY
Percentage of Subjects With Amenorrhea, Cycle 2, MITT Population
30.7 —
SECONDARY
Percentage of Subjects With Amenorrhea, Cycle 6, MITT Population
42.9 —
SECONDARY
Percentage of Subjects With Amenorrhea, Cycle 13, MITT Population
49.1 —

Eligibility Criteria

Inclusion Criteria

  • Healthy Women
  • Age 18-45
  • At risk for pregnancy
  • History of regular cycles

Exclusion Criteria

  • Contraindications for use of hormonal contraception
  • Conditions which affect the absorption or metabolism of steroid hormones
  • BMI > 35
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00391807). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search